MiMedx Group Statistics
Total Valuation
MiMedx Group has a market cap or net worth of $1.06 billion. The enterprise value is $960.46 million.
| Market Cap | 1.06B |
| Enterprise Value | 960.46M |
Important Dates
The next estimated earnings date is Wednesday, October 29, 2025, after market close.
| Earnings Date | Oct 29, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MiMedx Group has 147.96 million shares outstanding. The number of shares has decreased by -8.26% in one year.
| Current Share Class | 147.96M |
| Shares Outstanding | 147.96M |
| Shares Change (YoY) | -8.26% |
| Shares Change (QoQ) | -0.24% |
| Owned by Insiders (%) | 1.76% |
| Owned by Institutions (%) | 45.97% |
| Float | 108.77M |
Valuation Ratios
The trailing PE ratio is 33.92 and the forward PE ratio is 25.61.
| PE Ratio | 33.92 |
| Forward PE | 25.61 |
| PS Ratio | 2.90 |
| Forward PS | 2.59 |
| PB Ratio | 4.90 |
| P/TBV Ratio | 5.73 |
| P/FCF Ratio | 18.57 |
| P/OCF Ratio | 18.25 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.87, with an EV/FCF ratio of 16.81.
| EV / Earnings | 29.85 |
| EV / Sales | 2.64 |
| EV / EBITDA | 17.87 |
| EV / EBIT | 22.22 |
| EV / FCF | 16.81 |
Financial Position
The company has a current ratio of 4.39, with a Debt / Equity ratio of 0.09.
| Current Ratio | 4.39 |
| Quick Ratio | 3.74 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | 0.33 |
| Debt / FCF | 0.32 |
| Interest Coverage | 21.67 |
Financial Efficiency
Return on equity (ROE) is 16.61% and return on invested capital (ROIC) is 12.79%.
| Return on Equity (ROE) | 16.61% |
| Return on Assets (ROA) | 10.37% |
| Return on Invested Capital (ROIC) | 12.79% |
| Return on Capital Employed (ROCE) | 17.95% |
| Revenue Per Employee | $434,616 |
| Profits Per Employee | $38,437 |
| Employee Count | 837 |
| Asset Turnover | 1.40 |
| Inventory Turnover | 2.70 |
Taxes
In the past 12 months, MiMedx Group has paid $12.33 million in taxes.
| Income Tax | 12.33M |
| Effective Tax Rate | 27.84% |
Stock Price Statistics
The stock price has increased by +16.59% in the last 52 weeks. The beta is 1.74, so MiMedx Group's price volatility has been higher than the market average.
| Beta (5Y) | 1.74 |
| 52-Week Price Change | +16.59% |
| 50-Day Moving Average | 6.89 |
| 200-Day Moving Average | 7.63 |
| Relative Strength Index (RSI) | 54.10 |
| Average Volume (20 Days) | 473,681 |
Short Selling Information
The latest short interest is 5.02 million, so 3.40% of the outstanding shares have been sold short.
| Short Interest | 5.02M |
| Short Previous Month | 5.00M |
| Short % of Shares Out | 3.40% |
| Short % of Float | 4.62% |
| Short Ratio (days to cover) | 5.39 |
Income Statement
In the last 12 months, MiMedx Group had revenue of $363.77 million and earned $32.17 million in profits. Earnings per share was $0.21.
| Revenue | 363.77M |
| Gross Profit | 296.30M |
| Operating Income | 43.23M |
| Pretax Income | 63.47M |
| Net Income | 32.17M |
| EBITDA | 53.74M |
| EBIT | 43.23M |
| Earnings Per Share (EPS) | $0.21 |
Balance Sheet
The company has $118.87 million in cash and $18.46 million in debt, giving a net cash position of $100.41 million or $0.68 per share.
| Cash & Cash Equivalents | 118.87M |
| Total Debt | 18.46M |
| Net Cash | 100.41M |
| Net Cash Per Share | $0.68 |
| Equity (Book Value) | 216.62M |
| Book Value Per Share | 1.46 |
| Working Capital | 170.59M |
Cash Flow
In the last 12 months, operating cash flow was $58.12 million and capital expenditures -$990,000, giving a free cash flow of $57.13 million.
| Operating Cash Flow | 58.12M |
| Capital Expenditures | -990,000 |
| Free Cash Flow | 57.13M |
| FCF Per Share | $0.39 |
Margins
Gross margin is 81.45%, with operating and profit margins of 11.88% and 8.84%.
| Gross Margin | 81.45% |
| Operating Margin | 11.88% |
| Pretax Margin | 12.17% |
| Profit Margin | 8.84% |
| EBITDA Margin | 14.77% |
| EBIT Margin | 11.88% |
| FCF Margin | 15.71% |
Dividends & Yields
MiMedx Group does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 8.26% |
| Shareholder Yield | 8.26% |
| Earnings Yield | 3.03% |
| FCF Yield | 5.39% |
Analyst Forecast
The average price target for MiMedx Group is $12.00, which is 67.36% higher than the current price. The consensus rating is "Buy".
| Price Target | $12.00 |
| Price Target Difference | 67.36% |
| Analyst Consensus | Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
MiMedx Group has an Altman Z-Score of 10.79 and a Piotroski F-Score of 6.
| Altman Z-Score | 10.79 |
| Piotroski F-Score | 6 |